Therefore, we tested a potent, highly specific, and clinically approved LSD1 pharmacological inhibitor developed by the GlaxoSmithKline Company (GSK2879552) for cancer therapy, particularly for acute myeloid leukemia (AML) and small lung cancer cells (SCLC) [44]. The gene discussed is KDM1A; the disease is small cell lung carcinoma.